Episode: 77 - Derek Lowe on AI and the US Biotech Ecosystem

About this episode

Derek Lowe discusses the impact of AI and automation on drug discovery and the biotech ecosystem with host Christopher Bahl.

September 16, 2025 | With the rise of AI and automation, what is the core human skill in drug discovery that is and will be valuable in the future? Derek Lowe, director of Chemical Biology Therapeutics at Novartis and author of the In the Pipeline blog, discusses the impact of AI—and non-AI technologies—on the business of drug making. With host Christopher Bahl, cofounder and CEO of AI Proteins, their conversation covers the value of a PhD in the tech world today, the long-term impacts of kno...

People in this episode

Host: Christopher Bahl

Guest: Derek Lowe

Topics covered

• AI in drug discovery
• biotech ecosystem
• impact of automation
• value of PhD
• future skills in biotech

Keywords

• AI
• drug discovery
• biotech
• automation
• PhD value
• Derek Lowe
• Christopher Bahl

Mentioned in this episode

Organizations: Novartis, AI Proteins

More episodes of The Chain: Protein Engineering Podcast

• Episode: 86 - PANEL DISCUSSION: Near-Term Challenges for ML/AI in Biotherapeutic R&D · June 9, 2026 · 54 min
• Episode: 85 - Daniel Chen on Building Multi-Target Drugs with Logic Gating · May 12, 2026 · 47 min
• Episode: 84 - Martin Pacesa on BindCraft: An Automated Pipeline for De Novo Protein Binder Design · April 15, 2026 · 39 min
• Episode: 83 - Patrick Baeuerle and Jeffrey Miller on T Cell and Immune Cell Engagement · March 17, 2026 · 59 min
• Episode: 82 - PANEL DISCUSSION: Future of Biologic Therapeutics: Will Half-Life Extended Peptides Replace Multispecific Antibodies? · February 10, 2026 · 49 min
• Episode: 81 - Laszlo Radvanyi on Pushing Boundaries in Cancer Immunotherapy Research · January 13, 2026 · 44 min